Watch now

Free Seminar Programme

As an extra meeting place between exhibitors, visitors & press located on the show floor, speakers have 45 minutes to educate the industry about their products, services, new launches, innovations and news.

  • Dates: 28 - 30 August 2018
  • Venue: Seminar rooms A&B in the exhibion hall

2018 Special Seminar Programme Schedule (Free)

  Korean English Japanese
Date Time Title Organisation/
Company
Seminar Room
8.28 (Tue) 16:00 ~
17:00
Current State of Biopharmacutical Market in Japan
Development trends of Cancer Immunotherapy Drugs
Former JPMA
Former Astellas Korea
A
8.30 (Thu) 10:15 ~
11:00
Discussion on practical use of AI technologies in a specific stage of the Pharma supply chain; CRO, Drug Development, Marketing, etc
IQVIA A

2018 Seminar Programme Schedule (Free)

Pharmaceutical Technology and Regulations
Korean English
Date Time Title Organisation/
Company
Seminar Room
8.29 (Wed) 10:15 ~
11:00
Bacterial anti-adhesion : an indispensible tool for health care providers
PHARMATOKA S.A.S A
10:15 ~
12:00
Thai BioPharma: Your New Business Opportunities
Thailand Board
of Investment
B
15:00 ~
15:45
GRANFILLER-D, a Co-Processed Excipient for High-Performance Orally Disintegrating Tablets
Daicel
Corporation
A
15:00 ~
15:45
Measures to Implement the Nagoya Protocol on ABS for Industrial Sector
NIBR B
Pharmaceutical Services (Logistics, CRO)
Korean English
Date Time Title Organisation/
Company
Seminar Room
8.28 (Tue) 15:00 ~
15:45
Security Embedded Temp-controlled Transportation for Pharmaceutical Safety
Brink's Global Services Korea A
8.29 (Wed) 11:15 ~
12:00
Data Integrity assurance as a key factor for surviving corporate audits and regulatory
PQE A
13:00 ~
13:45
Security Embedded Temp-controlled Transportation for Pharmaceutical Safety
Brink's Global Services Korea A
14:00 ~
14:45
Improved Synthetic Planning With Reaxys
Elsevier A
Biopharmaceuticals
Korean English Japanese
Date Time Title Organisation/
Company
Seminar Room
8.28 (Tue) 15:00 ~
15:45
Biosimilar Comparability & Extrapolation Strategies: EU vs. Emerging Markets
RegPak BioPharma B
Laboratory Equipments
Korean
Date Time Title Organisation/
Company
Seminar Room
8.29 (Wed) 13:00 ~
13:45
Introduction of PCD for cGMP's Energy Save & Pressure Control
Lydia Company B
8.30 (Thu) 11:15 ~
12:00
UHPLC for Your Innovative Lab
YL Instruments A
11:15 ~
12:00
Introduction of PCD for cGMP's Energy Save & Pressure Control
Lydia Company B
Health Ingredients
English
Date Time Title Organisation/
Company
Seminar Room
8.29
(Wed)
14:00 ~
14:45
HRB (Human Residence Bifidobacteria) of Morinaga
MORINAGA MILK INDUSTRY CO., LTD. B
8.30
(Thu)
14:00 ~
14:45
HRB (Human Residence Bifidobacteria) of Morinaga
MORINAGA MILK INDUSTRY CO., LTD. A

2018 Seminar Speakers

Matsutaro Fujii
ex. Director, International Affairs, JPMA (2015~2018)
Former President & CEO of Astellas Korea Inc. (2008~2011)
Special Seminar 1  - 16:00 -17:00, Tuesday, August 28
Speaker Profile:
ex. Director, International Affairs, JPMA (2015~2018)
Former President & CEO of Astellas Korea Inc. (2008~2011)
Introduction:
The current (Bio)Pharmaceutical market situation in Japan will be presented and discussed, especially focused on Anti-Cancer, Biologics, Generics and Bio-similar products. There might be some hints for foreign company to enter into Japanese market.

Hywel Evans
Director, Analytics Center of Excellence, IQVIA
Special Seminar 2  - 10:15 - 11:00, Thursday, August 30
Speaker Profile:
Hywel leads IQVIA's Analytics Center of Excellence in Asia Pacific, delivering analytics solutions across the clinical and commercial areas of the business. These solutions include site selection models for clinical trials, commercial effectiveness models to optimize salesforce activity and generating digital insights from online data sources. Hywel has also worked across sales, marketing and digital, where he has designed customer engagement strategies and marketing programs. He is an analytics expert with 16 years' experience in consulting, data science and technology and has worked across Healthcare, Life Sciences, Consumer Goods, Manufacturing, Retail, Telco and Banking.
Introduction:
Discussion on practical use of AI technologies in a specific stage of the Pharma supply chain; CRO, Drug Development, Marketing, etc.

H.E.Mr.Singtong Lapisatepun
Ambassador of the Kingdom of Thailand to the Republic of Korea

Ms.Vannipa Pipupchaiyasit,
Minister-Counsellor(Investment)
10:15 - 12:00, Wednesdsay, August 29
Introduction:
10:15-10:30
Registration
10:30-10:40
Opening Remarks by H.E.Mr.Singtong Lapisatepun, Ambassador of the Kingdom of Thailand to the Republic of Korea
10:40-11:10
Business Opportunity & incentive for Pharmaceutical area and government support in Thailand by Ms.Vannipa Pipupchaiyasit, Minister-Counsellor(Investment) ,BOI,Seoul
11:10-11:40
Overview of Law & Taxation in Thailand
11:40-12:00
Q&A

Gunter Haesaerts
CEO
PHARMATOKA S.A.S
10:15 - 11:00, Wednesday, August 29
Introduction:
THE CONCEPT : Bacterial anti-adhesion means that pathogenic bacteria cannot adhere anymore to receptor cells and will be evacuated from the body by natural ways THE CLAIM : A traditional herbal medicinal product used to help prevent recurrent uncomplicated acute urinary tract infections (UTIs) such as cystitis in women only, based on traditional use only.

Tomohito Okabayashi
Application specialist, Pharma Solutions New Business Development
DAICEL CORPORATION
15:00 - 15:45, Wednesday, August 29
Introduction:
Orally Disintegrating Tablets (ODTs) differ from conventional tablets which are designed to dissolve rapidly in contact with saliva. It serves as alternative dosage form for who have difficulty in swallowing, such as small children and elderly people. GRANFILLER-D is a state-of-the-art Co-Processed Excipient for direct compression ODTs. In this presentation, we will explain few examples of API indicating high dose, content uniformity and wide taste masking alternatives.. With unique ideas and technical support, Daicel can provide the best solution for you..

TBA
NIBR(National Institute of Biological Resources)
15:00 - 15:45, Wednesday, August 29
Introduction:
Measures to Implement the Nagoya Protocol on ABS for Industrial Sector.

May Jungmi Lee
Life Sciences Manager
Brink's Global Services Korea
15:00 - 15:45, Tuesday, August 28 / 10:15 - 11:00, Wednesday , August 29
Introduction:
Pharmaceuticals is one of the main industries which requires security standards of transportation. Based on TAPA (The Transport Asset Protection Association) standards, we will look through what we can do to secure your supply chain for pharmaceutical safety. Brink's case study for shipping validation of temperature controlled vehicle would help to complement the integrity and safety of your supply chain.

Giacomo Cappellari
Business Development Director
PQE
11:15 - 12:00, Wednesday, August 29
Introduction:
Data integrity issues were the most striking findings in the last two years. European and US investigators found data manipulation, cover-ups with faked test results, uneven paper trails, destroyed or misplaced records, backdated production reports.

Data integrity lapses have become so widespread globally, that even the World Health Organization stepped in last year to issue guidance to bridge the gaps between the principles of good data and record management and actual practices.

Most of the 2016/2017 Warning letters urged companies to hire a third-party consultant with expertise in data integrity and GMP issues, and drug makers were urged to review their entire organizational structure and personnel responsibilities. This current regulatory enforcement for Data Integrity (see also recent guidelines from FDA, MHRA and WHO) call for the establishment of Data Governance as the holistic answer to the needs of Data Integrity based on the ALCOA requirements. Consequently Computer System Validation is moving from technology driven to data driven: the electronic records life cycle, based upon the intended use of the system, becomes the ultimate target of each validation exercise.

The current regulatory environment make the Data Integrity Assurance the key factor for the success in regulatory bodies and corporates inspections.

Alice Hong
Solution Sales Manager
Elsevier
14:00 - 14:45, Wednesday, August 29
Introduction:
In the highly competitive world of research and development, the ability to quickly retrieve relevant answers from the literature gives research groups a significant edge in terms of productivity.

Chemists in academic and corporate labs recognize the inefficiency of reading through full-text original sources, especially given the already vast and increasing volume of available literature.
A clear desire has emerged for a research solution that delivers the information researchers need rather than just directing them to source texts.

In this time, we will share the Life Science Solution of Elsevier and what is new in Reaxys Ver.2 which the largest chemical database in the world for year 2018, and will show you how we can get the answers about raw material medicine synthesis from new version of Reaxys. .

Parminder Kaur
Founder & RA/PV Consultant (EU-QPPV)
RegPak BioPharma
15:00 - 15:45, Tuesday, August 28
Speaker Profile:
Parminder Kaur is a regulatory expert and an EU QPPV with more than 20 years of recognised global expertise in a broad range of therapy areas. She has also played a major role in setting the in-house RA and PV systems in compliance with the European regulations.

Parminder had also been a speaker, panellist and Masterclass provider at various international Conferences. Parminder is currently running her own regulatory affairs and pharmacovigilance consultancy, RegPak BioPharma Consulting based in Amsterdam.
Introduction:
Developing a biosimilar and bringing it to market can be a lengthy and expensive process. It is crucial for sponsor organizations to understand the regulatory requirements that are currently set in order to develop strategies to allow biosimilar drugs to get the approval without major hurdles.

This session will present strategies for overcoming scientific, regulatory and legal challenges in the development and commercialization of biosimilars from EU versus the Emerging markets.

TBA
YL Instruments
11:15 - 12:00, Thursday, August 30
Introduction:
UHPLC for Your Innovative Lab.

Dosun Hong
CEO
Lydia Company
13:00 - 13:45, Wednesday, August 29 / 11:15-12:00, Thursday, August 30
Introduction:
Introduction of OKAYA SEIRITSU Company PCD, which is the optimal solution of pressure relief management, energy saving, and TAB validation of GMP factory, hospital, and research institute, which is more demanded through WHO's Guide Line along with BIO industry growth.

Saki Yamashita
Assistant Leader, International Division
MORINAGA MILK INDUSTRY CO., LTD.
   
Kiyoshi Nakamura
Leader, International Division
MORINAGA MILK INDUSTRY CO., LTD.
14:00 - 14:45, Wednesday, August 29 / 14:00 - 14:45, Thursday, August 30
Introduction:
1. The reason why we should pay attention to Bifidobacteria as Probiotic.
2. The difference between HRB(Human Residential Bifidobacteria) and non HRB.
3. Introduction of Morinaga Milk Indutry's Bifidobacteria based on scientific treatise.